{"id":"loratadine-montelukast","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Dizziness"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-10%","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Loratadine works by selectively inhibiting peripheral H1 receptors, which are responsible for the symptoms of allergies, such as itching, sneezing, and runny nose. Montelukast, on the other hand, works by blocking the action of cysteinyl leukotrienes, which are involved in the inflammatory response and airway constriction associated with asthma and allergies.","oneSentence":"Loratadine is an antihistamine that blocks the action of histamine, a substance in the body that causes allergy symptoms, while montelukast is a leukotriene receptor antagonist that blocks the action of leukotrienes, substances in the body that cause inflammation and constriction of airways.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:19:26.137Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Perennial allergic rhinitis"},{"name":"Chronic idiopathic urticaria"},{"name":"Asthma"}]},"trialDetails":[{"nctId":"NCT07101445","phase":"PHASE4","title":"Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial","status":"RECRUITING","sponsor":"Emory University","startDate":"2025-09-24","conditions":"Multiple Myeloma","enrollment":94},{"nctId":"NCT06019728","phase":"PHASE4","title":"A Prospective Study to Investigate Safety and Tolerability of Shorter Infusion of Fabrazyme","status":"COMPLETED","sponsor":"Sanofi","startDate":"2023-11-10","conditions":"Fabry's Disease","enrollment":8},{"nctId":"NCT01673620","phase":"PHASE3","title":"A Study to Evaluate the Safety of Combination Montelukast/Loratadine in Mexican Participants With Allergic Rhinitis (MK-0476A-484)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2012-07-04","conditions":"Allergic Rhinitis","enrollment":69},{"nctId":"NCT00423995","phase":"PHASE3","title":"Effect of Loratadine/Montelukast Combination on Congestion in SAR Patients Exposed to Pollen in an EEU (Study P04822)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-11-01","conditions":"Seasonal Allergic Rhinitis","enrollment":379},{"nctId":"NCT00319995","phase":"PHASE3","title":"Effects of Loratadine/Montelukast vs Pseudoephedrine and Placebo in Patients With Seasonal Allergic Rhinitis (Study P04095) (COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-03-01","conditions":"Rhinitis, Allergic, Seasonal","enrollment":1095},{"nctId":"NCT00979901","phase":"PHASE3","title":"Montelukast in Patients With Seasonal Allergic Rhinitis - Spring 2000 Study (MK-0476A-162)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2000-03","conditions":"Seasonal Allergic Rhinitis","enrollment":1577},{"nctId":"NCT00963599","phase":"PHASE3","title":"Montelukast in Seasonal Allergic Rhinitis - Fall 1999 Study (0476A-117)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"1999-09","conditions":"Seasonal Allergic Rhinitis","enrollment":907},{"nctId":"NCT00960141","phase":"PHASE3","title":"A Study Investigating the Effect of Montelukast in Patients With Seasonal Allergic Rhinitis (MK-0476-192)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2000-08","conditions":"Seasonal Allergic Rhinitis","enrollment":829},{"nctId":"NCT00972738","phase":"PHASE3","title":"Montelukast in Seasonal Allergic Rhinitis - Spring 2001 Study (0476-235)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2001-04","conditions":"Seasonal Allergic Rhinitis","enrollment":1214},{"nctId":"NCT00963469","phase":"PHASE3","title":"Montelukast in Seasonal Allergic Rhinitis: Fall 2001 Study (0476-240)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2001-08","conditions":"Seasonal Allergic Rhinitis","enrollment":1079},{"nctId":"NCT03372473","phase":"PHASE3","title":"Montelukast and Loratadine in Children With Asthma","status":"COMPLETED","sponsor":"Innovacion y Desarrollo de Estrategias en Salud","startDate":"2016-01-10","conditions":"Asthma in Children","enrollment":80}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":13,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"loratadine; montelukast","genericName":"loratadine; montelukast","companyName":"Organon and Co","companyId":"organon-and-co","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Loratadine is an antihistamine that blocks the action of histamine, a substance in the body that causes allergy symptoms, while montelukast is a leukotriene receptor antagonist that blocks the action of leukotrienes, substances in the body that cause inflammation and constriction of airways. Used for Perennial allergic rhinitis, Chronic idiopathic urticaria, Asthma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}